Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Indian Council of Medical Research
Deal Size : Undisclosed
Deal Type : Partnership
ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 cl ..
Details : Under the partnership, ICMR will engage in collaborative research on a small molecule for multiple myeloma with Aurigene oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 14, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Indian Council of Medical Research
Deal Size : Undisclosed
Deal Type : Partnership
Aurigene Reports Positive Outcomes from CAR-T Cell Therapy Phase 1 Trial
Details : DRL-1801 (ribrecabtagene autoleucel) is a novel autologous BCMA directed CAR-T cell therapy. It is being evaluated in patients for the treatment of relapsed/refractory multiple myeloma.
Product Name : DRL-1801
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 10, 2024
Reset All
